Retigabine: Chemical synthesis to clinical application

CNS Drug Reviews

Volumn 11, Issue 1, 2005, Pages 1-20

  Blackburn Munro, Gordon ^a   Dalby Brown, W ^a   Mirza, N R ^a   Mikkelsen, J D ^a   Blackburn Munro, R E ^a  

^a NEUROSEARCH A S   (Denmark)

Author keywords

Anxiety; Epilepsy; Kv7 channel; KCNQ; M current; Pain

Indexed keywords

10,10 BIS(4 PYRIDINYLMETHYL) 9(10H) ANTHRACENONE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; AWD 21 360; CARBAMAZEPINE; CARBON 14; DESAZAFLUPIRTINE DERIVATIVE; DIAZEPAM; FLUPIRTINE; GABAPENTIN; LAMOTRIGINE; LINOPIRDINE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PENTETRAZOLE; PHENOBARBITAL; PHENYTOIN; PICROTOXIN; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KCNQ1; RETIGABINE; TRAMADOL; UNCLASSIFIED DRUG; VALPROIC ACID;

AMYGDALOID NUCLEUS; ANXIETY; ASTHENIA; CLINICAL TRIAL; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; EPILEPSY; HEADACHE; HUMAN; KINDLING; MEMBRANE POTENTIAL; NAUSEA; NERVE EXCITABILITY; NEUROPATHIC PAIN; NEUROTOXICITY; NONHUMAN; POTASSIUM CHANNEL KV7; POTASSIUM CURRENT; REVIEW; SOMNOLENCE;

EID: 17744364985     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2005.tb00033.x     Document Type: Review

References (101)

1. Adamec RE, Morgan HD. The effect of kindling of different nuclei in the left and right amygdala on anxiety in the rat. Physiol Behav 1994;55:1-12.
2. Anisman H, Kelly O, Hayley S, et al. Acoustic startle and fear-potentiated startle in rats selectively bred for fast and slow kindling rates: Relation to monoamine activity. Eur J Neurosci 2000;12:4405-4416.
3. Armand V, Rundfeldt C, Heinemann U. Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by 4-aminopyridine in rat entorhinal cortex hippocampal slices. Naunyn Schmiedebergs Arch Pharmacol 1999;359:33-39.
4. Backonja M. Anticonvulsants and antiarrhythmics in the treatment of neuropathic pain syndromes. In: Hansson PT, et al., Eds. Neuropathic pain: Pathophysiology and treatment. IASP Press; 2001:185-201.
5. Bartolomeil F, Guye M, Wendling F, et al. Fear, anger and compulsive behavior during seizure: Involvement of large scale fronto-temporal neural networks. Epileptic Disord 2002;4:235-241.
6. Biervert C, Schroeder BC, Kubisch C, et al. A potassium channel mutation in neonatal human epilepsy. Science 1998;279:403-406.
7. Blackburn-Munro G. Pain-like behaviours in animals: How human are they? Trends Pharmacol Sci 2004;6: 299-305.
8. Blackburn-Munro G, Skaaning Jensen B. The anticonvulsant retigabine attenuates nociceptive behaviours in animal models of persistent and neuropathic pain. Eur J Pharmacol 2003;460:109-116.
9. Brown BS, Yu SP. Modulation and genetic identification of the M channel. Prog Biophys Mol Biol 2000;73: 135-166.
10. Chang BS, Lowenstein DH. Epilepsy. N Engl J Med 2003;349:1257-1266.
11. Davis M. Animal models of anxiety based on classical conditioning: The conditioned emotional response (CER) and the fear-potentiated startle effect. Pharmacol Ther 1990;47:147-165.
12. Davis M. The role of the amygdala in fear and anxiety. Annu Rev Neurosci 1992;15:353-375.
13. + channel. Proc Natl Acad Sci USA 2001;98: 12272-12277.
14. Dennison Z, Teskey GC, Cain DP. Persistence of kindling: Effect of partial kindling, retention interval, kindling site, and stimulation parameters. Epilepsy Res 1995;21:171-182.
15. De Sarro G, Di Paola ED, Conte G, Pasculli MP, De Sarro A. Influence of retigabine on the anticonvulsant activity of some antiepileptic drugs against audiogenic seizures in DBA/2 mice. Naunyn Schmiedebergs Arch Pharmacol 2001;363:330-336.
16. + channel. J Neurosci 2004;24: 1236-1244.
17. Dieter H-R, Engel J, Kutscher B, Polymeropoulos E, Szelenyi S, Nickel B. EP 0 554 543 B1, 1996.
18. Dost R, Rostock A, Rundfeldt C. The anti-hyperalgesic activity of retigabine is mediated by KCNQ potassium channel activation. Naunyn Schmiedebergs Arch Pharmacol 2004;369:382-390.
19. ++ model in the hippocampal slice preparation. Epilepsy Res 2000;38:53-66.
20. Dupuis DS, Schroder RL, Jespersen T, et al. Activation of KCNQ5 channels stably expressed in HEK293 cells by BMS-204352. Eur J Pharmacol 2002;437:129-137.
21. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: Diagnosis, mechanisms, and treatment recommendations. Arch Neurol 2003;60:1524-1534.
22. Ferron GM, Paul J, Francillo R, et al. Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers. J Clin Pharmacol 2002;42:175-182.
23. Friedel HA, Fitton A. Flupirtine. A review of its pharmacological properties, and therapeutic efficacy in pain states. Drugs 1993;45:548-569.
24. Ferron GM, Patat A, Parks V, Rolan P, Troy SM. Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects. Br J Clin Pharmacol 2003;56:39-45.
25. Geller I, Seifter J. The effects of meprobamate, barbiturate, D-amphetamine and promazine on experimentally-induced conflict in the rat. Psychopharmacologia 1960;1:482-492.
26. Gutman GA, Chandy KG, Adelman JP, et al. International Union of Pharmacology. XLI. Compendium of voltage-gated ion channels: potassium channels. Pharmacol Rev 2003;55:583-586.
27. Hadley JK, Passmore GM, Tatulian L, et al. Stoichiometry of expressed KCNQ2/KCNQ3 potassium channels and subunit composition of native ganglionic M channels deduced from block by tetraethylammonium. J Neurosci 2003;23:5012-5019.
28. Hempel R, Schupke H, McNeilly PJ, et al. Metabolism of retigabine (D-23129), a novel anticonvulsant. Drug Metab Dispos 1999;27:613-622.
29. Hermann R, Ferron GM, Erb K, et al. Effects of age and sex on the disposition of retigabine. Clin Pharmacol Ther 2003;73:61-70.
30. Hermann R, Knebel NG, Neibch G, Richards L, Borlak J, Locher M. Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects. Eur J Clin Pharmacol 2003;58:795-802.
31. Hetka R, Rundfeldt C, Heinemann U, Schmitz D. Retigabine strongly reduces repetitive firing in rat entorhinal cortex. Eur J Pharmacol 1999;386:165-171.
32. Hiller A, Nguyen N, Strassburg CP, et al. Retigabine N-glucuronidation and its potential role in enterohepatic circulation. Drug Metab Dispos 1999;27:605-612.
33. Ishikawa K, Tanaka M, Black JA, Waxman SG. Changes in expression of voltage-gated potassium channels in dorsal root ganglion neurons following axotomy. Muscle Nerve 1999;22:502-507.
34. Jentsch TJ. Neuronal KCNQ potassium channels: Physiology and role in disease. Nat Rev Neurosci 2000;1: 21-30.
35. Kapetanovic IM, Yonekawa WD, Kupferberg HJ. The effects of D-23129, a new experimental anticonvulsant drug, on neurotransmitter amino acids in the rat hippocampus in vitro. Epilepsy Res 1995;22:167-173.
36. Knebel NG, Grieb S, Leisenheimer S, Locher M. Determination of retigabine and its acetyl metabolite in biological matrices by on-line solid-phase extraction (column switching) liquid chromatography with tandem mass spectrometry. J Chromatogr B Biomed Sci Appl 2000;748:97-111.
37. LeDoux J. The emotional brain, fear, and the amygdala. Cell Mol Neurobiol 2003;23:727-738.
38. Loscher W. Animal models of drug-resistant epilepsy. Novartis Found Symp 2002;243:149-159.
39. Luben V, Muller H, Lobisch M, Worz R. Treatment of tumor pain with flupirtine. Results of a double-blind study versus tramadol. Fortschr Med 1994;112:282-286.
40. Main MJ, Cryan JE, Dupere JR, Cox B, Clare JJ, Burbidge SA. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol Pharmacol 2000;58:253-262.
41. Marrion NV. Control of M-current. Annu Rev Physiol 1997;59:483-504.
42. Matsuda S, Peng H, Yoshimura H et al. Persistent c-fos expression in the brains of mice with chronic social stress. Neurosci Res 1996;26:157-170.
43. Meisel P, Landgraf K-F, Schäfer J, et al. US Patent 5,914,425, 1999.
44. Millan MJ. The neurobiology and control of anxious states. Prog Neurobiol 2003;70:83-244.
45. Mineka S, Zinbarg R. Conditioning and ethological models of anxiety disorders: Stress-in-dynamic-context anxiety models. Nebr Symp Motiv 1996;43:135-210.
46. Mohapel P, McIntyre DC. Amygdala kindling-resistant (SLOW) or -prone (FAST) rat strains show differential fear responses. Behav Neurosci 1998;112:1402-1413.
47. Muzina DJ, El-Sayegh S, Calabrese JR. Antiepileptic drugs in psychiatry-focus on randomized controlled trial. Epilepsy Res 2002;50:195-202.
48. McMahon FG, Arndt WF Jr, Newton JJ, Montgomery PA, Perhach JL. Clinical experience with flupirtine in the U.S. Postgrad Med J 1987;63(Suppl 3):81-85.
49. McNeilly PJ, Torchin CD, Anderson LW, Kapetanovic IM, Kupferberg JH, Strong JM. In vitro glucuronidation of D-23129, a new anticonvulsant, by human liver microsomes and liver slices. Xenobiotica 1997;27: 431-441.
50. Nielsen AN, Mathiesen C, Blackburn-Munro G. Pharmacological characterisation of acid-induced muscle allodynia in rats. Eur J Pharmacol 2004;487:93-103.
51. Njung'e K, Handley SL. Evaluation of marble-burying behavior as a model of anxiety. Pharmacol Biochem Behav 1991;38:63-67.
52. Pare D, Collins DR. Neuronal correlates of fear in the lateral amygdala: Multiple extracellular recordings in conscious cats. J Neurosci 2000;20:2701-2710.
53. Pascoe JP, Kapp BS. Electrophysiological characteristics of amygdaloid central nucleus neurons in the awake rabbit. Brain Res Bull 1985;14:331-338.
54. Passmore GM, Selyanko AA, Mistry M, et al. KCNQ/M currents in sensory neurons: Significance for pain therapy. J Neurosci 2003;23:7227-7236.
55. Petersen EN, Lassen JB. A water lick conflict paradigm using drug experienced rats. Psychopharmacology 1981;75:236-239.
56. Quirk GJ, Gehlert DR. Inhibition of the amygdala: Key to pathological states? Ann NY Acad Sci 2003;985: 263-272.
57. Quirk GJ, Repa C, LeDoux JE. Fear conditioning enhances short-latency auditory responses of lateral amygdala neurons: Parallel recordings in the freely behaving rat. Neuron 1995;15:1029-1039.
58. Rasband MN, Park EW, Vanderah TW, Lai J, Porreca F, Trimmer JS. Distinct potassium channels on pain-sensing neurons. Proc Natl Acad Sci USA 2001;23:13373-13378.
59. Rauch SL, Shin LM, Wright CI. Neuroimaging studies of amygdala function in anxiety disorders. Ann NY Acad Sci 2003;985:389-410.
60. Ringe JD, Miethe D, Pittrow D, Wegscheider K. Analgesic efficacy of flupirtine in primary care of patients with osteoporosis related pain. A multivariate analysis. Arzneimittelforschung 2003;53:496-502.
61. Rivera-Arconada I, Martinez-Gomez J, Lopez-Garcia JA. M-current modulators alter rat spinal nociceptive transmission: An electrophysiological study in vitro. Neuropharmacology 2004;46:598-606.
62. + channels and the molecular pathogenesis of epilepsy: Implications for therapy. Trends Neurosci 2000;23:393-398.
63. Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004;5:553-564.
64. Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med 2004;10:685-692.
65. Rosen JB, Hamerman E, Sitcoske M, et al. Hyperexcitability: Exaggerated fear-potentiated startle produced by partial amygdala kindling. Behav Neurosci 1996;110:43-50.
66. Rostock A, Tober C, Rundfeldt C, et al. D-23129: A new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res 1996;23:211-223.
67. + channels in neuronal cells. Eur J Pharmacol 1997;336:243-249.
68. + channel opening effect of the anticonvulsant retigabine in PC12 cells. Epilepsy Res 1999;35:99-107.
69. Rundfeldt C, Netzer R. Investigations into the mechanism of action of the new anticonvulsant retigabine. Interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels. Arzneimittelforschung 2000;50:1063-1070.
70. Rundfeldt C, Netzer R. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells transfected with human KCNQ2/3 subunits. Neurosci Lett 2000;282:73-76.
71. + channels in brain. J Neurosci 2001;21:4609-4624.
72. A receptor blockade in the basolateral amygdala of rats. J Pharmacol Exp Ther 1997;283:969-977.
73. Sajdyk TJ, Shekhar A. Excitatory amino acid receptors in the basolateral amygdala regulate anxiety responses in the social interaction test. Brain Res 1997;764:262-264.
74. Sanders SK, Morzorati SL, Shekhar A. Priming of experimental anxiety by repeated subthreshold GABA blockade in the rat amygdala. Brain Res 1995;699:250-259.
75. Savonenko A, Filipkowski RK, Werka T et al. Defensive conditioning-related functional heterogeneity among nuclei of the rat amygdala revealed by c-Fos mapping. Neuroscience 1999;94:723-733.
76. Scheef W. Analgesic efficacy and safety of oral flupirtine in the treatment of cancer pain. Postgrad Med J 1987;63(Suppl 3):67-70.
77. Schroder RL, Jespersen T, Christophersen P, Strobaek D, Jensen BS, Olesen SP. KCNQ4 channel activation by BMS-204352 and retigabine. Neuropharmacology 2001;40:888-898. Erratum in: Neuropharmacology 2003;44:553.
78. Schroder RL, Jespersen T, Christophersen P, Strobaek D, Jensen BS, Olesen SP. KCNQ4 channel activation by BMS-204352 and retigabine. Neuropharmacology 2001;40:888-898. Erratum in: Neuropharmacology 2003;44:553.
79. + channels causes epilepsy. Nature 1998;396:687-690.
80. Shepherd JK, Grewal SS, Fletcher A, et al. Behavioural and pharmacological characterisation of the elevated "zero-maze" as an animal model of anxiety. Psychopharmacology 1994;116:56-64.
81. Sindrup SH, Jensen TS. Antidepressants in the treatment of neuropathic pain. In: Hansson PT, et al., Eds. Neuropathic pain: Pathophysiology and treatment. IASP Press; 2001:169-183.
82. Singh NA, Charlier C, Stauffer D, et al. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat Genet 1998;18:25-29.
83. Stables JP, Bertram E, Dudek FE, et al. Therapy discovery for pharmacoresistant epilepsy and for disease-modifying therapeutics: Summary of the NIH/NINDS/AES models II workshop. Epilepsia 2003;44: 1472-1478.
84. Strassburg CP, Strassburg A, Kneip S. Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut 2002;50:259-265.
85. Straub H, Kohling R, Hohling J et al. Effects of retigabine on rhythmic synchronous activity of human neocortical slices. Epilepsy Res 2001;44:155-165.
86. Sullivan GM, Apergis J, Gorman JM et al. Rodent doxapram model of panic: Behavioral effects and c-Fos immunoreactivity in the amygdala. Biol Psychiatry 2003;53:863-870.
87. Tatulian L, Brown DA. Effect of the KCNQ potassium channel opener retigabine on single KCNQ2/3 channels expressed in CHO cells. J Physiol 2003;549:57-63.
88. Tatulian L, Delmas P, Abogadie FC, Brown DA. Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine. J Neurosci 2001;21: 5535-5545.
89. Tober C, Rostock A, Rundfeldt C, Bartsch R. D-23129: A potent anticonvulsant in the amygdala kindling model of complex partial seizures. Eur J Pharmacol 1996;303:163-169.
90. Vogel JR, Beer B, Clody DE. A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacologia 1971;21:1-7.
91. Wang HS, Pan Z, Shi W, et al. KCNQ2 and KCNQ3 potassium channel subunits: Molecular correlates of the M-channel. Science 1998;282:1890-1893.
92. Waxman SG. The molecular pathophysiology of pain: Abnormal expression of sodium channel genes and its contributions to hyperexcitability of primary sensory neurons. Pain 1999;6(Suppl):S133-140.
93. Wickenden AD, Rigdon GC, McNaughton-Smith GA, Gross MF. US Patent 6,326,385 B1; 2001.
94. Wickenden AD, Roeloffs R, McNaughton-Smith G, Rigdon GC. KCNQ potassium channels: Drug targets for the treatment of epilepsy and pain. Expert Opin Ther Patents 2004;14:457-469.
95. Wickenden AD, Yu W, Zou A, Jegla T, Wagoner PK. Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol 2000;58:591-600.
96. Wickenden AD, Zou A, Wagoner PK, Jegla T. Characterization of KCNQ5/Q3 potassium channels expressed in mammalian cells. Br J Pharmacol 2001;132:381-384.
97. Woolf CJ, Salter MW. Neuronal plasticity: Increasing the gain in pain. Science 2000;288:1765-1769.
98. Worz R. Flupirtine in chronic myofacial pain conditions. Fortschr Med 1991;109:158-160.
99. Worz R, Bolten W, Heller B, Krainick JU, Pergande G. Flupirtine in comparison with chlormezanone in chronic musculoskeletal back pain. Results of a multicenter randomized double-blind study. Fortschr Med 1996;114:500-504.
100. Yonekawa WD, Kapetanovic IM, Kupferberg HJ. The effects of anticonvulsant agents on 4-aminopyridine induced epileptiform activity in rat hippocampus in vitro. Epilepsy Res 1995;20:137-150.
101. Yus-Najera E, Munoz A, Salvador N, et al. Localization of KCNQ5 in the normal and epileptic human temporal neocortex and hippocampal formation. Neuroscience 2003;120:353-364.